-
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
•
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV) with Taiwan-headquartered Rxilient Biotech to develop and commercialize its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), across Southeast Asia. The agreement covers key territories including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.…
-
Novartis’ Kisqali Demonstrates Improved iDFS in Phase III NATALEE Study for Early Breast Cancer
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III NATALEE study has achieved its primary endpoint of invasive disease-free survival (iDFS). The study assessed the efficacy of Kisqali (ribociclib) in combination with endocrine therapy (ET) for hormone receptor-positive/human epidermal growth factor receptor 2 negative…
-
Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study
•
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced that its IL-4Rα monoclonal antibody (mAb) drug candidate, CM310, has successfully reached its primary endpoints in a confirmatory Phase III clinical study for the treatment of moderate to severe atopic dermatitis (AD). Phase III Study…
-
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
•
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based in China, has joined forces with Venus Medtech (Hangzhou) Inc., another prominent player in the medical field (HKG: 2500), to announce the establishment of a partnership fund. Each company is contributing RMB 125 million (USD…
-
AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030
•
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the UK-based pharmaceutical giant is planning to triple its investment in research and development in China over the coming months. This strategic move aims to increase the number of innovative drugs entering the Chinese market, as…
-
Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the fourth quarter of 2022. The company reported Q4 revenues of CNY 142.2 million (USD 20.6 million), marking a 3.5% decrease year-on-year (YOY). However, for the full 12 months, revenues showed a positive trend, increasing by…
-
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
•
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius Bio’s HLX208, and LianBio’s infigratinib are all set to be awarded priority review status as Category 1 chemical drugs. TQB3454: A Promising IDH1 Mutase InhibitorTQB3454 is an in-house developed IDH1 mutase inhibitor intended for the…
-
Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment
•
Brii Biosciences has announced a strategic decision to end the manufacturing and further development of the amubarvimab/romlusevimab combination treatment regimen for COVID-19. According to the company’s recent 2022 financial report, the antibody cocktail had been commercially available in China from July 2022 following an emergency use authorization (EUA) and had…
-
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
•
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary of BGI Group (SHE: 300676), based in China. The collaboration aims to localize and transform comprehensive cancer care by introducing automation platforms for sequencing pipelines across the entire cycle of precise diagnosis and treatment of…
-
PharmaBlock Expands US Presence with New R&D Facility in West Chester
•
PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a new R&D facility in West Chester, Pennsylvania. This strategic move aims to expand the company’s presence in the United States and offer more efficient process R&D services, enabling the fast delivery of clinical-stage GMP projects…
-
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s Otezla (apremilast) has obtained marketing approval from the National Medical Products Administration (NMPA), signifying that it has passed the generic quality and efficacy consistency evaluation. Apremilast’s Background and Clinical Necessity in ChinaApremilast, an oral small…
-
NMPA Introduces Procedures to Adjust Chemical Generic Reference Preparations
•
The National Medical Products Administration (NMPA) has released a document outlining procedures for the adjustment of “Chemical Drug Generic Reference Preparation,” which are set to take effect immediately. This move aims to streamline and update the reference preparations for generic drugs in China, ensuring alignment with current pharmacopoeia standards and…
-
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
•
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK). This strategic partnership will see the combination of BJ Bio’s pipeline candidate, BJ-001, with MSD’s programmed death-1 (PD-1) inhibitor, Keytruda (pembrolizumab), in a Phase I clinical trial…
-
Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval for its Vericor peripheral support catheter from the Thailand Food and Drug Administration. This development marks a significant step for the company as it expands the reach of its medical devices in the Southeast Asian…
-
CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008
•
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a Phase II trial for its pipeline candidate CAN008 (asunercept) in combination with temozolomide for the treatment of glioblastoma multiforme (GBM). The multi-center, randomized, placebo-controlled study, which is potentially registrational, has recruited a total of 117…
-
Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review
•
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing for its in-house developed Category 1 biological product, Xeligekimab, for the treatment of moderate to severe plaque psoriasis has been accepted for review. This development marks a significant step forward for the company and the…
-
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022. As of December 31, 2022, the company reported revenues of RMB 9.382 billion (USD 1.362 billion), a decrease of 5.6% year-on-year (YOY). Despite this, the sales revenue of innovative drugs reached RMB 5.006 billion (USD…
-
National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety
•
The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual Report (2022)”, providing insights into the adverse drug reaction (ADR) landscape in China. The National Adverse Drug Reaction Monitoring Network received 2,023,000 ADR/Event Report Forms and 642,000 new and serious ADR/Event reports during the year.…
-
China’s New Internet Advertising Regulations Impact Pharmaceutical Sector
•
The State Administration for Market Regulation has released the latest version of the “Measures for the Administration of Internet Advertising,” which came into effect on May 1, 2023. The new rules have significant implications for the pharmaceutical industry, including the following key points: Prohibition on Internet Advertising of Prescription DrugsThe…
-
Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for 2022, highlighting revenues of RMB 43.952 billion (USD 6.381 billion), marking a 12.66% increase year-on-year (YOY). The company’s net profits also saw a significant rise, reaching RMB 3.873 billion (USD 562.4 million), up 18.17%…
